Mechanism of Action
Truncated IGF-1 variant lacking N-terminal tripeptide; reduced IGFBP binding affinity in some tissues enables more immediate IGF-1R access and localised anabolic pathway activation (PI3K/Akt/mTOR, Ras/MAPK) with shorter systemic duration than IGF-1 LR3.
Simplified Summary
IGF-1 DES is a naturally-occurring truncated variant of IGF-1, missing its first three N-terminal amino acids. This structural difference reduces its binding affinity to IGF-binding proteins (IGFBPs) in some tissue contexts, which means the compound is not sequestered by circulating binding proteins as efficiently as full-length IGF-1, enabling more immediate receptor access.
The compound's shorter half-life (approximately 30 minutes) and site-specific administration protocol position it as a research tool for studying local rather than systemic IGF-1 signalling. Research protocols typically involve injection at or near target tissue sites (commonly trained muscle groups) to investigate localised anabolic pathway activation.
IGF-1 DES is distinguished from IGF-1 LR3 (which has an extended half-life and systemic reach) by its shorter duration of action and reduced systemic exposure profile. These different pharmacokinetic characteristics make them useful for different experimental questions in IGF-1 axis research.
Key Findings Reported in Research Models
- Receptor binding profile: Biochemical studies have characterised IGF-1 DES's reduced IGFBP binding affinity in specific tissue contexts, supporting its use as a tool for studying IGF-1R signalling with reduced binding protein interference.
- Localised anabolic pathway activation: Cell culture and site-specific injection research has examined whether IGF-1 DES produces more localised tissue responses than systemically-acting IGF-1 variants, with downstream PI3K/Akt/mTOR pathway analyses.
- Hypoglycaemia risk: Research has characterised dose-dependent hypoglycaemia as a safety consideration, present with IGF-1 DES as with other IGF-1 variants, requiring proximate carbohydrate availability in research protocols.
- Short pharmacokinetic window: Approximately 30-minute half-life has been characterised in pharmacokinetic research, defining daily post-workout administration as the standard research timing window.
- Dose range characterisation: Research protocols have examined doses from 30–150 mcg for subcutaneous site-specific administration, with the 4-week maximum cycle length emerging from safety-focused investigation of extended IGF-1R stimulation.
Introduction
IGF-1 DES (des(1-3)IGF-1) was identified as a naturally-occurring variant in human brain tissue and other biological contexts before synthetic research applications were developed. The truncation removes three N-terminal amino acids (glycine-proline-glutamic acid), which reduces but does not eliminate IGFBP binding in specific tissue environments.
The research rationale for IGF-1 DES parallels that for site-specific growth factor delivery — using a shorter-acting form that clears rapidly to minimise systemic exposure while allowing investigation of local tissue responses. This contrasts with IGF-1 LR3, which is modified specifically to extend systemic half-life for prolonged systemic effect research.
FDA regulatory status reflects the broader IGF-1 compound class: mecasermin (Increlex) is approved for GH insensitivity syndrome using full-length recombinant IGF-1, but the truncated DES variant lacks approved indication. The compound is classified in FDA Category 2 for compounding (significant safety risk).
Research Applications
- Local IGF-1 signalling research: Site-specific injection models for investigating localised IGF-1R activation, PI3K/Akt/mTOR pathway engagement, and tissue-specific anabolic responses.
- Comparative IGF-1 pharmacology: Head-to-head comparisons with IGF-1 LR3 and full-length IGF-1 to characterise the functional consequences of IGFBP-binding differences in various tissue systems.
- Safety and hypoglycaemia biology: Dose-response studies examining the glucose-lowering effects of IGF-1 variants and the mechanisms underlying post-injection hypoglycaemia risk.
What to Expect
Early signalling is underway; most researchers note mild subjective changes by end of week one.
Downstream biological effects should be detectable. Mid-cycle assessment is appropriate.
Full washout and data review. Given limited human data, results should be documented carefully for your research log.
Frequently Asked Questions
For research use only. Capital Products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.